What the research found

Butyrate—a short-chain fatty acid produced when your gut microbes ferment fibre—influences multiple aspects of colonic health, from maintaining low oxygen environments to modulating immune signalling. Two delivery strategies have emerged to target butyrate to the lower gut where it's most needed: tributyrin (a triglyceride form that bacteria must break down) and ProButyrate (a delayed-release capsule formulation). A SHIME study (an in vitro model of the human colon) examined how tributyrin behaves during passage through simulated gut conditions. The key distinction between these approaches lies in when and where butyrate is released and becomes available to colonic tissue—tributyrin requires microbial metabolism to liberate butyrate, while ProButyrate is engineered to release it at a specific pH.

Why it matters for you

If you're using butyrate supplementation to support gut barrier function, reduce inflammation, or optimise your microbiome—especially if you track inflammatory markers like fCal or zonulin—the formulation you choose likely affects outcomes. Standard butyrate salts are absorbed too quickly in the proximal colon; delayed-release versions were developed specifically to extend butyrate delivery distally, where the majority of immune tissue resides and where colonic health problems often originate. Your tolerance and response may depend on which form you're using. Tributyrin-based products work indirectly (bacteria do the work), which could be slower but may suit people with dysbiosis differently than direct-release formulations. If you've noticed butyrate worsens constipation, this is real—its stool-forming properties mean timing relative to your gut motility matters, particularly if you're also managing sleep or training load via circadian optimisation.

Caveats

  • SHIME is an in vitro model; it simulates but does not replicate the living complexity of a human colon
  • No direct head-to-head human trials comparing tributyrin to ProButyrate appear to be cited
  • Information on ProButyrate mechanisms came from direct communication with manufacturers, not peer-reviewed studies
  • This remains an area of significant unknowns—clinical efficacy differences between formulations have not been rigorously characterized
  • Individual variation in microbiota composition will likely influence how effectively tributyrin is converted to butyrate